Clinical trials: Neuromyelitis Optica Spectrum Disorders
Autoimmune Disease
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory…
- Trial name
- NCT06633042
- Testing
- Universal BCMA-CD19 CART
- Volunteers
- 18 people
- Sponsor
- Bioray Laboratories
Neuromyelitis Optica Spectrum Disorders (NMOSD)
BLAZE-Limiting Approach in NMOSD
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651).
- Trial name
- NCT06888622
- Testing
- Eculizumab administration
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Huashan Hospital
Multiple Sclerosis, MS, Neuromyelitis Optica Spectrum Disorders
Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions.
- Conditions
- Multiple Sclerosis, MS, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Acute Disseminated Encephalomyelitis
- Trial name
- NCT06541626
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
AIRE Deficiency
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
Studying genetic predisposition in autoimmune neurological diseases could help improve diagnostic accuracy and offer new treatment possibilities
- Trial name
- NAD-AIRE (NCT06941584)
- Testing
- Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay, AIRE single gene sequencing, Molecular typing of HLA class I and II alleles
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06485232
- Testing
- Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xuanwu Hospital, Beijing
NMO Spectrum Disorder
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel.
- Trial name
- NCT05154734
- Testing
- Belimumab
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis, NMO Spectrum Disorder
China National Registry of Neuro-Inflammatory Diseases
Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases
- Trial name
- CNRID (NCT05154370)
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Tiantan Hospital
Neuromyelitis Optica Spectrum Disorders
Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
To clarify the efficacy and safety of protein A immunoadsorption therapy for acute exacerbations of neuromyelitis optica spectrum disorders(NMOSD), we designed a multicenter, open-label, superiority randomized controlled clinical…
- Trial name
- PANDA (NCT06763848)
- Testing
- Protein A immunoadsorption, intravenous methylprednisolone
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University